Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Surgical Procedures, Operative 18Granulocyte Colony-Stimulating Factor 18Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16anlotinib 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma × pidilizumab × Clear all
NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡